Publications by authors named "M D Voss"
Background: Historically, soil-transmitted helminth (STH) control and prevention strategies have relied on mass drug administration efforts targeting preschool and school-aged children. While these efforts have succeeded in reducing morbidity associated with STH infection, recent modeling efforts have suggested that expanding intervention to treatment of the entire community could achieve transmission interruption in some settings. Testing the feasibility of such an approach requires large-scale clinical trials, such as the DeWorm3 cluster randomized trial.
View Article and Find Full Text PDFPurpose: Clinical trials enable renal cell carcinoma (RCC) patients to receive promising investigational agents, yet access may be limited. Telemedicine (TM) is an increasingly utilized platform that can expand access, but perspectives on its use in clinical trial care are unknown.
Patients And Methods: A prospective study was conducted between Jan 2023 - Oct 2023 at Memorial Sloan Kettering Cancer Center.
Purpose: We report 5-year oncologic outcomes of a prospective series of patients with prostate cancer treated with spot-scanning proton therapy (SSPT).
Methods And Materials: A prospective registry identified patients with prostate cancer treated with SSPT between January 2016 and December 2018. Five-year overall survival, local control, biochemical failure, regional and distant failures, and adverse events (AEs) were assessed.
Article Synopsis
- Glycosylation is crucial for modifying lipids and sorting proteins, with its regulation involving a unique distribution of enzymes in the Golgi and the action of SPPL3.
- In cells lacking the retention factor LYSET/TMEM251, there is increased secretion of a Golgi protein, B4GALT5, due to disrupted M6P tagging, which typically marks proteins for lysosomal degradation.
- The study reveals that GOLPH3 and GOLPH3L adaptors play a critical role in stabilizing the LYSET-GNPT complex, maintaining proper Golgi function, and ensuring efficient lysosomal enzyme processing.
Background: Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6-9 months. 3,4-Dihydroxy-6-[F]fluoro-L-phenylalanine (F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy.
View Article and Find Full Text PDF